Bispecific Antibody Therapies Show Promise for Elderly
New clinical evaluations suggest effective alternatives to standard chemotherapy for frail lymphoma patients.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you trust that new medical therapies can make cancer treatments safer for elderly patients?
Researchers have been testing bispecific antibody therapies as a safer treatment option for elderly patients with diffuse large B-cell lymphoma. These newer regimens aim to address the limitations of traditional chemotherapy in frail populations.
Why it matters
Standard R-mini-CHOP chemotherapy often leads to poor outcomes and significant toxicity in elderly patients who cannot tolerate full treatment cycles. These antibody therapies represent a strategic shift toward reducing treatment-related complications while maintaining high efficacy.
A study evaluating rituximab, polatuzumab vedotin, and glofitamab yielded a 1-year progression-free survival rate of 85% and overall survival of 90%. Additionally, epcoritamab monotherapy achieved an overall response rate of 70% in elderly patients.
The players
Memorial Sloan Kettering
This New York City-based cancer center is a leader in advanced oncology research and clinical trials.
MD Anderson Cancer Center
Located in Houston, this institution is one of the world's most prominent centers for cancer patient care and research.
The details
Clinicians utilize the Simplified Geriatric Assessment to identify patients 80 years and older who are classified as frail. These therapies, which can include epcoritamab and mosunetuzumab, are being evaluated to minimize risks like neurotoxicity and cytokine release syndrome.
Timeline
Historically, R-CHOP has served as the standard of care for decades.
Current assessments of bispecific antibodies are actively ongoing as of September 2026.
The Big Picture
This development moves the field away from the traditional reliance on the R-mini-CHOP chemotherapy protocol. It signals a shift toward precision-based immunotherapy for elderly populations who were previously underserved by standard cytotoxic options.
These findings could lead to more tolerable treatment options that significantly reduce the risk of severe infections and neurotoxicity for elderly patients. Families can expect more personalized treatment plans that rely on geriatric assessments rather than one-size-fits-all chemotherapy.
The takeaway
Advancements in bispecific antibodies offer a promising path for reducing the physical burden of cancer treatment on the elderly. Patients and their caregivers should consult with oncologists about whether targeted immunotherapy is a suitable alternative to traditional chemotherapy.
What happens next
Updated follow-up data for the glofitamab study is expected to provide 2-year survival results in future clinical reporting.
Further reading
For more information on current treatment trends, visit our Cancer section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Do you trust that new medical therapies can make cancer treatments safer for elderly patients?
